REDBUD LABS Broadens MXR™ Chip Offering

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

RESEARCH TRIANGLE PARK, N.C., May 23, 2019 /PRNewswire/ — Redbud Labs (“Redbud”) announced today an expansion to its MXRTM (“mixer”) microfluidic chip family with the introduction of MXRTM BLUE. The new MXR BLUE line of chips is a new formulation of the company’s proprietary Redbud PostTM technology that maintains maximum performance in sample-to-answer cartridges without the need for additives. Like all of Redbud’s chip products, MXR BLUE is cartridge-readyTM and optimal for use in point-of care molecular tests.

Redbud's MXR microfluidic chipRedbud's MXR microfluidic chip

MXR BLUE is designed for use in a wide range of applications, especially for system developers seeking to improve diagnostic sensitivity, shorten time-to-result, or simplify the consumable for a multiplexed genomic or proteomic test. With MXR BLUE, assay developers can now flood chambers directly with raw biofluids such as blood or urine, cell media, pure water, and other high-surface tension fluids. This new model rounds out the MXR offering, and follows the March launch of STRTM, a cartridge-ready sample prep solution for microfluidic affinity sorting.

“We developed MXR BLUE based on customer demand,” reports Dr. Jay Fisher, Vice President of R & D. “Researchers and systems developers alike have been seeking out the mixing advantages of MXR, but were restricted in their ability to utilize surfactants in their assays. Thanks to MXR BLUE’s hydrophilic characteristics this is no longer an issue.  Developers can integrate the cartridge-ready chip into their protocols and immediately reap the rewards of MXR-enhanced mixing. With MXR BLUE, it’s now possible to work directly with non-diluted biological fluids like whole blood, urine, cerebral spinal fluid, saliva, synovial fluid, plasma, serum, etc.”

Redbud’s MXR chips are recognized for their rapid mixing capability in microfluidic volumes where reliance upon diffusion kinetics limits the performance of sample-to-answer assays. MXR chip models are assembled microfluidic components, well-suited for use with microarrays, reagent reconstitution and microfluidic cartridges. MXR BLUE comes in two standard chip assemblies. A wide range of made-to-order chips are also immediately available, thanks to Redbud’s rapid customization capabilities.

ABOUT REDBUD
Redbud Labs, headquartered in Research Triangle Park, North Carolina, manufacturers breakthrough components for life science industry, intended to solve the industry’s ubiquitous microscale fluidic challenges. Redbud technologies have broad application across a variety of segments including basic research, drug discovery and development, biomanufacturing, diagnostics, sequencing and applied markets. Industry partners seek Redbud’s proprietary microchip technology, component design expertise and deep scientific know-how to advance their own next generation products. Rebudlabs.com

For further information contact:

Kathryn Lawrence
VP Business Development
Redbud Labs
+1 919-537-9753 x97
lawrence@redbudlabs.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/redbud-labs-broadens-mxr-chip-offering-300856212.html

SOURCE Redbud Labs, Inc.

Staff

Recent Posts

HCP OneHealthPort Appoints New Director of External Affairs to Strengthen Strategic Partnerships and Community Engagement

SAMMAMISH, Wash., May 19, 2025 /PRNewswire/ -- HCP OneHealthPort, Washington state's leading nonprofit health data utility,…

15 minutes ago

CareConnect Announces New Partnership and ATS Integration with myCNAjobs to Bolster Hiring Solution

PORT WASHINGTON, N.Y., May 19, 2025 /PRNewswire/ -- CareConnect, LLC, a leader in homecare AI,…

16 minutes ago

eCOA Solutions Market worth US$4.78 billion by 2030 with 16.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., May 19, 2025 /PRNewswire/ -- The global eCOA solution market, valued at US$1.94…

16 minutes ago

Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition

Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer…

16 minutes ago